He previously served as chief of the combined Division of Hematology – Oncology from 2001-2017, when Hematology became a separate Division. Rosenblatt also currently serves as Associate Director for Faculty Development in the Sylvester Comprehensive Cancer Center and previously served as Interim Director of the Sylvester Comprehensive Cancer Center from 2010-2012. From 2001 -2017 he served as Associate Director for Clinical and Translational Research within the Sylvester Comprehensive Cancer Center.
Dr. Rosenblatt joined UM/Sylvester in September 2001 from the University of Rochester where he served as the Chief of the Hematology-Oncology Unit and Associate Director for Clinical Research at the James P. Wilmot Cancer Center from 1995-2001. He completed Medical School, Residency and Hematology –Oncology fellowship training at the University of California at Los Angeles , where he joined the faculty rising to the rank of Associate Professor.
Professor Rosenblatt is well known for research in the areas of human retroviruses, immune therapies for cancer, human gene therapy and antibody engineering has been a principal investigator on numerous grants from the National Institutes of Health, US Department of Defense, American Cancer Society and the Leukemia and Lymphoma Society of America.
He is a former member of National Cancer Institute Experimental Therapeutics II, and Clinical Immunology and Immunotherapy study sections, and has been a three time and current member of the international Israel Cancer Research Fund Scientific Review Panel.
DR Rosenblatt maintains an active clinical practice focused on lymphoid and other hematologic malignancies and has served as Principal Investigator on multiple clinical trials. Rosenblatt has served on scientific advisory panels for Merck, Seattle Genetics, Kite among others and most recently for Synergys – a biotechnology startup. He recently has been an academic co-investigator on two NCI SBIR grants.
In terms of clinical experience Dr. Lippman is board certified in internal medicine and sub specialty board certified in Medical Oncology and Endocrinology and Metabolism. he has taken care of patients in inpatient and outpatient settings for decades and trained innumerable medical students, house officers and oncology fellows. His clinical work has been recognized by his election as a Master of the American College of Physicians and the Royal College of Physicians as well as mentorship prizes from the university of Michigan and the university of Miami.
In terms of business activities, Dr. Lippman has joined Seattle genetics as head of their scientific advisory board at their inception in 1998 and shortly thereafter was elected to the Board of Directors on which he still serves. In that time Seattle Genetics has grown to a publicly traded company with a market cap of ~ 12 billion dollars.
He is the founder of a new biotechnology company [GENEYUS] which is developing drugs which target cancer oncogenes. For many years he was part of the biotech team of PERSEUS LLC which – in a series of funds – managed more than a billion dollars, approximately 25% of which was directed to biotechnology investments.